# Immedica's Loargys Cleared in Saudi Arabia for Arginase 1 Deficiency Patients Aged 2 and Up

> Immedica's Loargys wins Saudi approval for hyperargininemia in arginase 1 deficiency, the company's second marketing authorization in the kingdom.

- Published: 2026-11-16T12:42:19+00:00
- Section: Regulation & Approvals
- Author: News Desk
- URL: https://newsforagent.com/news/2026-11-16/immedica-loargys-saudi-approval
- Source: [news.cision.com](https://news.cision.com/immedica-pharma-ab/r/immedica-receives-marketing-authorization-approval-for-loargys---pegzilarginase--in-saudi-arabia,c4425050)

## Key takeaways

- The Saudi Food and Drug Authority approved Loargys (pegzilarginase) for hyperargininemia in arginase 1 deficiency patients aged 2 and older.
- Immedica said the approval is its second marketing authorization in Saudi Arabia.
- Loargys is approved in the EU, UK, US, Oman, Canada and Saudi Arabia.

Immedica has received marketing authorization from the Saudi Food and Drug Authority for Loargys (pegzilarginase) to treat hyperargininemia in adults, adolescents and children aged 2 and older with arginase 1 deficiency, used alongside dietary protein restriction. The Swedish company announced the approval on November 16, [news.cision.com](https://news.cision.com/immedica-pharma-ab/r/immedica-receives-marketing-authorization-approval-for-loargys---pegzilarginase--in-saudi-arabia,c4425050) reported.

## What the Saudi Approval Covers

[Immedica](https://akta.pro/company-profiles/0004scb/immedica) is a Stockholm-based pharmaceutical company focused on commercializing and developing medicines for rare diseases and specialty care. It was founded in 2018, employs around 200 people across Europe, the Middle East and the United States, and is backed by KKR and Impilo.

Loargys is a recombinant human arginase-1 enzyme that the company says rapidly and sustainably lowers plasma arginine and its toxic metabolites. Immedica describes it as the first and only therapy proven to lower plasma arginine. The drug is already approved in the EU, UK, US, Oman, Canada and Saudi Arabia.

ARG1-D is an ultra-rare inherited metabolic disorder in which plasma arginine and its toxic metabolites accumulate. Symptoms include spasticity, seizures, developmental delay, intellectual disability and early mortality, and patients are often diagnosed in late infancy or early childhood.

"The SFDA approval of Loargys is an important milestone for Immedica and for patients and families living with ARG1-D in Saudi Arabia," said Anders Edvell, CEO of Immedica. "This is our second marketing authorization approval in Saudi Arabia and reflects our continued commitment to addressing unmet medical needs in rare diseases."

## Loargys in Immedica's Regulatory Record

According to akta.pro [company records](https://akta.pro/company-data), the FDA granted accelerated approval to Loargys in February 2026 for arginase 1 deficiency in patients aged 2 and older, based on reduction of plasma arginine, with confirmatory studies required after approval. The same records show Immedica entered multiple new geographies between late 2025 and early 2026, including Ravicti approvals in Japan in December 2025 and in the UAE and Oman, and Ztalmy's first MENA authorization in Kuwait in April 2026.

## Earlier Steps Toward the Saudi Filing

In August 2026, Japan's Ministry of Health, Labor and Welfare granted Orphan Drug Designation to pegzilarginase for arginase 1 deficiency, making the drug eligible for a priority review process, news.cision.com reported. Immedica said it plans to submit a Japanese New Drug Application.

In June 2026, Immedica announced that the Emirates Drug Establishment granted marketing authorization for Ztalmy (ganaxolone) to treat seizures associated with CDKL5 deficiency disorder in the UAE, according to news.cision.com.

## What Comes Next for Immedica

Immedica said it plans to submit a Japanese New Drug Application for pegzilarginase following the orphan designation. The company also said it will advance IV ganaxolone into a new phase 3 study in refractory status epilepticus, planning to start in 2027.

## Companies in this story

- [Immedica company profile](https://akta.pro/company-profiles/0004scb/immedica) · website: http://www.immedica.com

---
News for Agent · https://newsforagent.com/llms.txt
